Kymera Therapeutics to Participate in Upcoming March Investor Conferences
01 March 2023 - 11:00PM
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage
biopharmaceutical company advancing targeted protein degradation to
deliver novel small molecule protein degrader medicines, today
announced that the Company’s management team will attend the
following upcoming investor events:
- Cowen 43rd Annual Health Care Conference in Boston, MA on March
6-8, 2023; Nello Mainolfi, PhD, Founder, President and CEO, will
participate in a fireside chat on March 6 at 10:30 AM ET, and the
Company will host 1x1 meetings
- Jefferies Biotech on the Bay Summit in Miami, FL on March
16-17, 2023; the Company will host 1x1 meetings only
A live webcast of the fireside chat will be available under the
"Events and Presentations" section of the Investors page on the
Company's website at www.kymeratx.com. A replay of the webcast will
be archived and available following the event.
About Kymera Therapeutics Kymera is a
biopharmaceutical company pioneering the field of targeted protein
degradation, a transformative approach to address disease targets
and pathways inaccessible with conventional therapeutics. Kymera’s
Pegasus platform is a powerful drug discovery engine, advancing
novel small molecule programs designed to harness the body’s innate
protein recycling machinery to degrade dysregulated,
disease-causing proteins. With a focus on undrugged nodes in
validated pathways, Kymera is advancing a pipeline of novel
therapeutic candidates designed to address the most promising
targets and provide patients with more effective treatments.
Kymera’s initial programs target IRAK4, IRAKIMiD, and STAT3 within
the IL-1R/TLR or JAK/STAT pathways, and the MDM2 oncoprotein,
providing the opportunity to treat patients with a broad range of
immune-inflammatory diseases, hematologic malignancies, and solid
tumors.
Founded in 2016, Kymera is headquartered in Watertown, Mass.
Kymera has been named a “Fierce 15” company by Fierce Biotech and
has been recognized by both the Boston Globe and the Boston
Business Journal as one of Boston’s top workplaces. For more
information about our people, science, and pipeline, please visit
www.kymeratx.com or follow us on Twitter or LinkedIn.
Investor
Contact: Bruce Jacobs Chief Financial
Officer investors@kymeratx.com 857-285-5300 Chris
Brinzey Managing Director,
Westwicke chris.brinzey@westwicke.com 339-970-2843 |
Media
Contact: Todd Cooper Senior Vice President,
Corporate Affairs media@kymeratx.com 857-285-5300 |
Kymera Therapeutics (NASDAQ:KYMR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kymera Therapeutics (NASDAQ:KYMR)
Historical Stock Chart
From Apr 2023 to Apr 2024